Peng Peng

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer

Qi Yu, Shumao Ni, Laura Sourd, 2022, Molecular cancer therapeutics.

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors

J. Ajani, F. Meric-Bernstam, S. Piha-Paul, 2024, The oncologist.